Guideline Recommendations for the Use of Potassium‑Competitive Acid Blockers (PCABs) versus Proton‑Pump Inhibitors (PPIs) in Acid‑Related Disorders

Mechanism of Action & Pharmacologic Profile

• PCABs directly and competitively inhibit the potassium‑binding site of the gastric H⁺/K⁺‑ATPase, providing immediate acid suppression without the need for pro‑drug activation. 2
• The acid‑stable formulation of PCABs eliminates the requirement for enteric coating and allows dosing independent of meals. 2
• PCABs have a longer plasma half‑life (approximately 6–9 h) than PPIs (1–2 h), enabling sustained binding to proton pumps as they become active throughout the day. 2
• PCAB therapy maintains intragastric pH > 4 for up to 85 % of a 24‑hour period, a proportion markedly higher than that achieved with standard PPIs. 2
• PPIs are pro‑drugs that require acid activation in the parietal‑cell canaliculus and must be taken 30–60 min before meals to coincide with post‑prandial pump activation. 1
• PPIs bind covalently and irreversibly to active pumps but have a shorter duration of availability compared with PCABs. 1
• PPIs are extensively metabolized by CYP2C19, producing significant inter‑patient variability in acid‑suppression efficacy based on genetic polymorphisms. 2

Efficacy by Indication

Severe Erosive Esophagitis (Los Angeles Grade C/D)

• PCABs (vonoprazan) achieve superior healing rates—91.7 % at 4 weeks and 88.5 % at 8 weeks—compared with standard‑dose PPIs. 1
• PCABs are recommended for patients with severe EE who have failed twice‑daily PPI therapy. 1

Mild‑to‑Moderate Erosive Esophagitis (Grade A/B)

• Standard‑dose PPIs remain the first‑line, cost‑effective therapy; PCABs are not indicated as initial treatment. 1
• PCABs may be reserved for documented PPI failure after optimization to twice‑daily dosing. 1

Non‑Erosive GERD (NERD) and Uninvestigated Heartburn

• PCABs are not advised as first‑line therapy; they may be considered only after confirmed failure of optimized (twice‑daily) PPI regimens. 1

Helicobacter pylori Eradication

• PCABs should replace PPIs in eradication regimens for the majority of patients, providing consistent eradication rates irrespective of CYP2C19 genotype. 1

Peptic Ulcer Disease (PUD)

• Routine PUD treatment or prophylaxis should start with PPIs; PCABs demonstrate non‑inferiority but lack a cost‑effectiveness advantage. 1

Bleeding Gastroduodenal Ulcers (High‑Risk Stigmata)

• PCABs have potential utility due to rapid, potent acid inhibition, but current evidence is insufficient to support routine use. 1

On‑Demand Therapy for Heartburn

• Evidence is currently inadequate to endorse PCABs as first‑line on‑demand therapy, despite a faster onset of symptom relief observed in limited trials. 1

Metabolism & Drug‑Interaction Considerations

• PCABs are not metabolized by CYP2C19, eliminating pharmacogenetic variability and ensuring uniform efficacy across all metabolizer phenotypes. 2
• PPIs (especially omeprazole and esomeprazole) strongly inhibit CYP2C19 and can diminish the antiplatelet effect of clopidogrel; pantoprazole is preferred when clopidogrel co‑therapy is required. 6

Safety Profile

• Both PCABs and PPIs are associated with an increased risk of Clostridioides difficile infection and other enteric infections due to profound acid suppression. 2
• PCAB therapy leads to higher serum gastrin levels than PPIs, which typically normalize within weeks after discontinuation. 2
• Observational data from Japan suggest a possible modest increase in gastric cancer risk with PCABs (adjusted HR < 2), comparable to that seen with PPIs. 2
• Long‑term safety data for PCABs are less extensive than the decades of post‑marketing surveillance available for PPIs. 1
• No maternal or developmental toxicity has been observed in animal studies of PCABs, although human pregnancy data remain limited. 2
• Chronic PPI use can cause rebound acid hypersecretion after discontinuation. 6

Cost, Accessibility & Economic Considerations

• PCABs are 10–20 times more expensive than generic PPIs; vonoprazan in particular carries a substantially higher price tag. 1
• The modest clinical superiority of PCABs in selected indications often does not justify their higher cost as first‑line therapy. 1
• Generic PPIs (e.g., pantoprazole, omeprazole) are widely available over‑the‑counter, whereas PCABs require prescription and frequently prior‑authorization. 7
• For standard acid‑related conditions, generic pantoprazole and omeprazole represent the most cost‑effective options. 6

Clinical Decision Algorithm

First‑Line Preference for PPIs

• Mild‑to‑moderate EE (LA A/B)
• NERD and uninvestigated heartburn
• Routine PUD treatment and prophylaxis
• Any acid‑related condition where PCAB superiority has not been established

Escalation to PCABs

• Severe EE (LA C/D) that fails twice‑daily PPI therapy
• H. pylori eradication regimens (PCAB‑based preferred)
• Documented acid‑related reflux refractory to optimized (twice‑daily) PPI therapy

Situations with Potential PCAB Utility (Insufficient Evidence)

• On‑demand heartburn therapy (rapid symptom relief)
• Bleeding gastroduodenal ulcers with high‑risk stigmata

Practical Considerations & Pitfalls

• Do not select PCABs solely for their pharmacologic advantages; weigh cost, accessibility, and limited long‑term safety data. 1
• Prior to labeling a patient as PPI‑refractory, ensure PPI therapy has been optimized to twice‑daily dosing and confirm disease severity with endoscopy. 1
• In patients receiving clopidogrel, avoid omeprazole or esomeprazole and use pantoprazole to minimize CYP2C19‑mediated drug interaction. 6
• Monitor for hypergastrinemia‑related complications (e.g., enterochromaffin‑like cell hyperplasia, neuroendocrine changes) during prolonged PCAB therapy. 2

All bullet points are supported by at least one cited reference; where multiple sources exist, the primary Gastroenterology 2024 citation has been prioritized.